CVS stock slides before the bell as Medicare Advantage rate shock hits insurers
27 January 2026
2 mins read

CVS stock slides before the bell as Medicare Advantage rate shock hits insurers

New York, Jan 27, 2026, 05:08 EST — Premarket

  • CVS Health shares dropped roughly 9% in premarket trading following a nearly flat 2027 Medicare Advantage payment update
  • CMS forecasted a modest net average rise of 0.09% year-over-year. Comments are due by Feb. 25, and the final rates will be set by April 6.
  • Traders are tuning into insurer earnings calls, hunting for early signals on pricing, benefits, and margin pressures

Shares of CVS Health (CVS) dropped roughly 9% in premarket trading Tuesday after U.S. health regulators announced a 2027 Medicare Advantage payment update that fell well short of investor expectations. The stock had closed Monday up about 1% at $83.87. 1

This shift is significant since Medicare Advantage, the private-sector alternative to traditional Medicare, ranks among the largest profit sources for major U.S. health insurers. A weaker payment forecast could push plans to cut benefits, hike premiums, or absorb rising medical expenses, all of which can pinch their profits.

The Centers for Medicare & Medicaid Services announced its 2027 “Advance Notice,” projecting a net average payment increase of 0.09% year over year—amounting to over $700 million—if the proposal is finalized. The update factors in medical cost trends, 2026 Star Ratings (which influence bonus payments), and adjustments to risk calculations. CMS has set a public comment deadline for Feb. 25 before issuing final rates by April 6. “These proposed payment policies are about making sure Medicare Advantage works better for the people it serves,” CMS Administrator Dr. Mehmet Oz said. 2

Risk adjustment—a system that boosts payments when members are sicker—is getting a tighter grip from CMS. The agency plans to exclude diagnoses from “unlinked” chart review records, according to its fact sheet. These changes add up to a 0.09% net impact. CMS also pointed out that, factoring in expected trends in coding and population shifts, the overall payment change would average 2.54%. 3

The policy announcement sent shockwaves through the sector. UnitedHealth and Humana plunged in after-hours trading, while CVS’s Aetna insurance unit came under heavy scrutiny. “People were estimating this flat rate nearer to 4 to 5% due to rising costs and usage in senior care insurance,” Kevin Gade, COO at Bahl & Gaynor, told Reuters. Morningstar’s Julie Utterback noted the industry will be closely watching if the agency tweaks its assumptions before the rule is finalized. 4

Some desks were already anticipating more than just the initial numbers. JPMorgan analyst Lisa Gill pointed out that preliminary Medicare Advantage rates have been bumped up in eight of the past 10 years. That track record might ease early jitters if CMS hints at flexibility. 5

The risk of cuts remains evident. America’s Health Insurance Plans, a trade industry group, cautioned that “flat program funding” combined with rising medical expenses and increased care usage might jeopardize seniors’ coverage. If the proposal goes through, insurers could reduce benefits or shift more costs to members. 6

CVS will deliver its next clear update soon, with fourth-quarter and full-year 2025 earnings set for Feb. 10. Investors will be focused on Aetna’s Medicare Advantage results following this rate update. 7

Traders will be closely watching the big insurers’ 2027 planning. Will they focus on benefit design, pricing discipline, and medical cost trends? Or hint that CMS might ease up on the final numbers?

The next major policy event is the comment deadline on Feb. 25, with CMS expected to release its final rate announcement by April 6. These dates could trigger another wave of volatility in the sector.

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Micron stock jumps in premarket on $24B Singapore fab plan as AI memory crunch tightens
Previous Story

Micron stock jumps in premarket on $24B Singapore fab plan as AI memory crunch tightens

Humana stock tumbles in premarket after CMS flags near-flat 2027 Medicare Advantage rates
Next Story

Humana stock tumbles in premarket after CMS flags near-flat 2027 Medicare Advantage rates

Go toTop